Paula Otero-Rodriguez

Pamplona, NC, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 139 publications

Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study.

Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study.

Journal: Future oncology (London, England)

Published: August 30, 2026

Correction: Haemostatic changes during CART cell therapy and risk of complications.

Correction: Haemostatic changes during CART cell therapy and risk of complications.

Journal: Cancer immunology, immunotherapy : CII

Published: August 25, 2026

A plain language summary describing how talquetamab affects the way people with multiple myeloma feel and function in the MonumenTAL-1 study.

A plain language summary describing how talquetamab affects the way people with multiple myeloma feel and function in the MonumenTAL-1 study.

Journal: Future oncology (London, England)

Published: June 16, 2026

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

Journal: The New England journal of medicine

Published: June 15, 2026

High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy.

High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Published: May 28, 2026

Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study.

Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study.

Journal: Blood advances

Published: April 03, 2026

MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma.

MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma.

Journal: Blood

Published: March 02, 2026

Talquetamab in patients with relapsed/refractory multiple myeloma: 3-year follow-up of the phase 1/2 MonumenTAL-1 study.

Talquetamab in patients with relapsed/refractory multiple myeloma: 3-year follow-up of the phase 1/2 MonumenTAL-1 study.

Journal: Blood

Published: February 25, 2026

Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma.

Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma.

Journal: Journal for immunotherapy of cancer

Published: February 25, 2026

Multiple myeloma: A tale of deregulated transcription factors.

Multiple myeloma: A tale of deregulated transcription factors.

Journal: HemaSphere

Published: February 19, 2026

Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myeloma.

Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myeloma.

Journal: Journal of medical economics

Published: February 17, 2026

Plain language summary of the management of certain side effects of teclistamab in people with multiple myeloma.

Plain language summary of the management of certain side effects of teclistamab in people with multiple myeloma.

Journal: Future oncology (London, England)

Published: January 23, 2026

Showing 1-12 of 139

Last Updated: 09/26/2026